US 12,102,510 B2
Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
Vihar C. Surti, Winston-Salem, NC (US); Shaun D. Gittard, Winston-Salem, NC (US); John C. Sigmon, Jr., Winston-Salem, NC (US); and Gregory Hardy, Asheville, NC (US)
Assigned to WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT, Wilmington, DE (US)
Filed by COOK MEDICAL TECHNOLOGIES LLC, Bloomington, IN (US)
Filed on Oct. 21, 2021, as Appl. No. 17/507,151.
Application 17/507,151 is a division of application No. 15/581,876, filed on Apr. 28, 2017, granted, now 11,931,227.
Application 15/581,876 is a continuation in part of application No. 14/209,718, filed on Mar. 13, 2014, abandoned.
Application 15/581,876 is a continuation in part of application No. 14/044,040, filed on Oct. 2, 2013, granted, now 9,867,931.
Claims priority of provisional application 61/793,586, filed on Mar. 15, 2013.
Prior Publication US 2022/0040006 A1, Feb. 10, 2022
Int. Cl. A61F 13/04 (2006.01); A61F 13/00 (2024.01); A61F 13/02 (2024.01); A61F 13/0246 (2024.01); A61L 15/22 (2006.01); A61L 15/58 (2006.01); A61L 24/00 (2006.01); A61L 26/00 (2006.01)
CPC A61F 13/04 (2013.01) [A61F 13/00063 (2013.01); A61F 13/023 (2013.01); A61F 13/0253 (2013.01); A61L 15/225 (2013.01); A61L 15/58 (2013.01); A61L 24/001 (2013.01); A61L 26/0061 (2013.01); A61L 2300/418 (2013.01); A61L 2400/04 (2013.01); A61L 2400/06 (2013.01)] 20 Claims
 
1. A method for protecting and treating a lesion with active bleeding in the gastrointestinal tract, comprising:
directly applying a hemostatic agent at and about a site of the lesion in the gastrointestinal tract in the amount and for a time sufficient to stop the active bleeding; and
once the active bleeding has stopped or slowed, directly applying a protective covering comprising an adhesive agent on top of and about at least a portion of the previously applied hemostatic agent, wherein the protective covering upon application on top of and about at least a portion of the hemostatic agent is in direct contact with both the hemostatic agent and tissue surrounding the lesion, provides a sustained protective barrier, and is capable of remaining at and about the site of the lesion for a minimum of 30 minutes.